Plasmablastic lymphoma
MONDO:0017347An aggressive diffuse large B-cell lymphoma frequently arising in the setting of HIV infection and characterized by the presence of large neoplastic cells resembling B-immunoblasts which have the immunophenotypic profile of plasma cells. Sites of involvement include the oral cavity, sinonasal cavity, skin, soft tissues, gastrointestinal tract, and bone.
Also known as: PBL, Plasmablastic lymphoma, PLBL
2024 clinical trials for this condition and its sub-types, 20 tagged with Plasmablastic lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
New hope for HIV patients with aggressive lymphoma: early trial launches
Disease control Not yet recruitingThis early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug aims to lock in remission for rare lymphoma
Disease control Not yet recruitingThis study tests whether the drug elranatamab can help keep plasmablastic lymphoma, a rare and aggressive blood cancer, from returning after initial chemotherapy. About 17 adults with or without HIV who have already responded to first treatment will receive elranatamab injections…
Phase 2/3 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC